Matt Clancy

Article

Matt Clancy is a recurring person in the Astral Codex Ten archive, appearing 3 times across 3 issues between September 22, 2022 and August 29, 2025. The archive places it in contexts such as “Matt Clancy published the idea first”; “Tamay Besiroglu vs. Matt Clancy”; “economist Matt Clancy estimates that each public and private R&D dollar yields roughly $5.50 in GDP”. It most often appears alongside Adam Neumann, Alex Roesch, Alignment Research Center.

Metadata

  • Category: People
  • Mention count: 3
  • Issue count: 3
  • First seen: September 22, 2022
  • Last seen: August 29, 2025

Appears In

Source Context

Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.

September 22, 2022 · Original source
Ironically, I wrote a draft of a post on this, but Matt Clancy published the idea first. I don’t know what I expected.
June 26, 2023 · Original source
A Debate About AI And Explosive Growth: Tamay Besiroglu vs. Matt Clancy. Will AI be just another invention that is probably good for the economy but leaves GDP trajectories overall unchanged? Or will it create a technoeconomic singularity leading to “impossibly” fast economic growth? A good followup for my recent Davidson On Takeoff Speeds. I don’t think they emphasized enough the claim that the natural trajectory of growth had long been trending towards a singularity in the 2020s, we only started deviating from that natural trajectory since ~1960 or so, and that we’re just debating whether AI will restore the natural curve rather than whether it will do some bizarre unprecedented thing that we should have a high prior against.
August 29, 2025 · Original source
The return on investment from research is compelling. Synthesizing the empirical literature, economist Matt Clancy estimates that each public and private R&D dollar yields roughly $5.50 in GDP—and about $11 when broader benefits are counted. Every dollar of NIH funding not deployed represents lost opportunities for breakthrough treatments, missed chances to train the next generation of scientists, and diminished returns on America's innovation ecosystem.